Successful treatment of congenital acute myeloid leukemia (AML-M6) in a premature infant.
Congenital acute myeloid leukemia (AML), and especially AML-M6 is a rare disease with a poor prognosis. Moreover, reports of treatment outcome of congenital AML-M6 in premature infants are not available. We report the first treated case of congenital AML-M6 in a premature girl, who received a full AML protocol. She presented with blueberry-muffin spots, anemia, high white blood cell count, and serious cardiopulmonary distress. Peripheral blood smears showed AML-M6 blasts. After treatment with a sequential low-dose cytarabine after birth and full-dose AML treatment according to the MRC-12 protocol at the age of 2 months, she now is in continuous complete remission for 4 years.
van Dongen
Joyce C A
JC
Department of Pediatric Oncology/Hematology, Erasmus University, Rotterdam, The Netherlands.
Dalinghaus
Michiel
M
Kroon
Andre A
AA
de Vries
Andrica C H
AC
van den Heuvel-Eibrink
Marry M
MM
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D003561:Cytarabine / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D012074:Remission Induction
D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine